Detailed Information on Publication Record
2021
Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery
CIBULA, David, Jiri SLAMA, Lukas DOSTALEK, Daniela FISCHEROVA, Anna GERMANOVA et. al.Basic information
Original name
Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery
Authors
CIBULA, David (203 Czech Republic, guarantor), Jiri SLAMA (203 Czech Republic), Lukas DOSTALEK, Daniela FISCHEROVA (203 Czech Republic), Anna GERMANOVA (203 Czech Republic), Filip FRUHAUF (203 Czech Republic), Pavel DUNDR (203 Czech Republic), Kristyna NEMEJCOVA (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Silvie SEBESTOVA (203 Czech Republic), Andrea BURGETOVA (203 Czech Republic), Martina BORCINOVA (203 Czech Republic) and Roman KOCIAN (203 Czech Republic)
Edition
British journal of cancer, London, Nature Publishing Group, 2021, 0007-0920
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 9.075
RIV identification code
RIV/00216224:14110/21:00120906
Organization unit
Faculty of Medicine
UT WoS
000598704600001
Keywords in English
cervical cancer; novel prognostic marker
Tags
International impact, Reviewed
Změněno: 8/4/2021 11:11, Mgr. Tereza Miškechová
Abstract
V originále
Background Models predicting recurrence risk (RR) of cervical cancer are used to tailor adjuvant treatment after radical surgery. The goal of our study was to compare available prognostic factors and to develop a prognostic model that would be easy to standardise and use in routine clinical practice. Methods All consecutive patients with early-stage cervical cancer treated by primary surgery in a single referral centre (01/2007-12/2016) were eligible if assessed by standardised protocols for pre-operative imaging and pathology. Fifteen prognostic markers were evaluated in 379 patients, out of which 320 lymph node (LN)-negative. Results The best predictive model for the whole cohort entailed a combination of tumour-free distance (TFD) <= 3.5 mm and LN positivity, which separated two subgroups with a substantially distinct RR 36% and 6.5%, respectively. In LN-negative patients, a combination of TFD <= 3.5 mm and adenosquamous tumour type separated a group of nine patients with RR 33% from the rest of the group with 6% RR. Conclusions A newly identified prognostic marker, TFD, surpassed all traditional tumour-related markers in the RR assessment. Predictive models combining TFD, which can be easily accessed on pre-operative imaging, with LN status or tumour type can be used in daily practice and can help to identify patients with the highest RR.